Company Releases Comprehensive Ingredient Research Guide to Address Consumer Confusion in Growing Brain Health Supplement Market ...

A new study has identified TRIM56, an E3 ubiquitin ligase, as a key activator of the proto-oncogene Src in hepatocellular ...

Ingelheim, Germany / Ridgefield, Connecticut, U.S.Data from the Phase Ib Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients ...

Ingelheim, Germany / Ridgefield, Connecticut, U.S. Data from the Phase Ib Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC were presented ...

Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopeniaRecommendation based on LUNA 3 phase 3 study ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the 'Company') announced that the Company's human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate (ADC) trastuzumab ...

Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response –OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd.

Johnson & Johnson today announced findings from the Phase 2 DAHLIAS study published in The Lancet showing that nipocalimab, an investigational FcRn treatment for Sjögren's disease (SjD), significantly ...

Get the latest on Novo Nordisk's Alzheimer's trial, stock outlook, and market risks. See what investors need to know before ...